OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Posadas on Unmet Needs in Prostate Cancer

September 13th 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.

Dr. Shain Discusses the Role of Stem Cell Transplant in Myeloma

September 12th 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCC

September 12th 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.

Dr. Raje Discusses the Impact of bb2121in Myeloma

September 12th 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.

Dr. Ho on Managing Immune-Related AEs in Kidney Cancer

September 11th 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.

Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option

September 11th 2018

Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.

Dr. Jotte on the Low Rate of Screening in Lung Cancer

September 11th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

September 11th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Dr. Shah Compares Toxicity Profiles of Ibrutinib and Acalabrutinib

September 11th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.

Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCL

September 10th 2018

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.

Dr. Papadimitrakopoulou on Impactful Targeted Therapies in Lung Cancer

September 10th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses impactful targeted therapies in lung cancer.

Dr. Gupta Discusses Combination Immunotherapy in RCC

September 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses combination immunotherapy in renal cell carcinoma.

Dr. Barrientos on Important Considerations for Patients with MCL

September 10th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses important considerations for patients with mantle cell lymphoma.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer

September 10th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

Dr. McCollum on Molecular Testing in CRC

September 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses molecular testing in patients with colorectal cancer (CRC).

Dr. Figlin Discusses the Future of Kidney Cancer Treatment

September 10th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Dr. Powell Discusses Data With Immunotherapy in Ovarian Cancer

September 8th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses data with immunotherapy in ovarian cancer.

Dr. Brander on the Treatment of Relapsed/Refractory CLL

September 8th 2018

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

September 8th 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.